A March 2026 compilation by the PIB highlights India’s consolidated position as the "Pharmacy of the World," ranking 3rd globally by volume and 11th by value. The sector, valued at $60 billion in 2025, is projected to reach $130 billion by 2030, supported by a turnover of ₹4.72 lakh crore in FY25.
India remains the largest global supplier of generic medicines (20% share) and provides 60% of the world's vaccine demand to UNICEF. This growth is anchored by a robust regulatory ecosystem including the CDSCO and the Indian Pharmacopoeia Commission (IPC), whose standards are now recognised in 19 countries. To move beyond generics, the government has proposed the Biopharma SHAKTI initiative with an outlay of ₹10,000 crore to establish India as a global hub for biologics and biosimilars.
Key Performance Indicators and Strategic Pillars
Export Strength: Pharmaceutical exports reached $30.5 billion in 2024-25, directed to 191 countries, with 50% of shipments going to highly regulated markets like the US and EU.
Foreign Investment: Drugs and Pharmaceuticals attracted ₹13,193 crore in FDI during the first half of FY25-26, signaling high international confidence.
PLI Success: Production Linked Incentive schemes have mobilized ₹40,890 crore in investment (as of Sept 2025) and avoided imports worth ₹3,591 crore in critical APIs and KSMs.
Trade Integration: Recently concluded or proposed FTAs with the EU, UK, and New Zealand are set to provide zero-duty access for Indian generics and medical devices across hundreds of tariff lines.
Affordability Hub: Over 18,646 Jan Aushadhi Kendras are operational as of March 2026, saving citizens an estimated ₹8,000 crore annually on essential medicines.
MedTech Growth: Medical device exports rose to $4.1 billion in 2024-25, supported by dedicated medical device parks in states like Tamil Nadu and Uttar Pradesh.
What is the "Biopharma SHAKTI" Initiative? Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) is a flagship initiative proposed in the Union Budget 2026-27 with a ₹10,000 crore outlay over five years. It plays a role in transitioning the Indian pharmaceutical industry from a leader in "small molecule" generics to a global manufacturing hub for complex "large molecule" biologics and biosimilars. The initiative is supported by the goal of upgrading 7 existing NIPERs and establishing 3 new ones to create an institutional network for advanced research. By creating over 1,000 accredited clinical trial sites, Biopharma SHAKTI reflects growth in India’s capacity to mechanically conduct high-value R&D, ensuring the country remains at the cutting edge of global healthcare innovation.
Policy Relevance: Anchoring the Global Healthcare Value Chain
Scaling Domestic Resilience: The reduction in import dependence for APIs and Drug Intermediates (DIs) through PLI schemes reflects growth in India's strategic autonomy during global supply chain disruptions.
Internalising Global Standards: Hosting the highest number of USFDA-approved plants outside the US plays a role in maintaining the "assured quality" tag that makes Indian medicines the preferred choice in 191 nations.
Bypassing High R&D Costs: The PRIP scheme and its Centres of Excellence are supported by the need to bridge the gap between academia and industry, already resulting in 6 patents and 111 approved research projects.
Supporting "Viksit Bharat" Health Goals: The expansion of the Jan Aushadhi network contributes to reducing out-of-pocket expenditure, a critical component of achieving universal health coverage by 2047.
Leveraging Digital Oversight: Just as JJM 2.0 uses digital tracking for water, the CDSCO's evolving regulatory framework and the Indian Carbon Market Portal'scd transparency standards reflect a broader move toward digitally-verified compliance in the pharma sector.
Relevant Question for Policy Stakeholders: What specific technical protocols will be used to ensure the 1,000 new clinical trial sites meet the data integrity standards required for international regulatory filings?
Follow the Full Compilation Here: India’s Pharmaceuticals in Global Healthcare
